We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.60 | -0.65% | 91.30 | 91.12 | 91.90 | 92.24 | 91.09 | 91.83 | 891,417 | 16:40:00 |
From May 2019 to May 2024
By Kim Richters
Sanofi SA said Thursday that the European Patent Office had ruled in favor of Sanofi and Regeneron Pharmaceuticals Inc. in a patent case related to their cholesterol drug Praluent.
The French pharmaceutical company said the European authority's ruling invalidated certain European patent claims made by Amgen Inc. concerning PCSK9 antibodies relevant to the drug.
U.S. pharmaceutical company Amgen wasn't immediately available for comment.
Sanofi said it owns the rights for the drug outside of the U.S., while Regeneron holds them inside the country.
Praluent continues to be on the market in the European countries where it is approved, with the exception of Germany following an injunction in July last year, which Sanofi said it has appealed.
Write to Kim Richters at kim.richters@wsj.com
(END) Dow Jones Newswires
October 29, 2020 10:43 ET (14:43 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
